Jump to section
To become the leading provider of primary cell culture solutions to enable life-saving therapies.
Cell culture is the base research of basic cell biology to replicate disease mechanisms, or investigate the toxicity of novel drug compounds. Created by a father-son team BioLamina is a biotech company contributing to the global health movement. Its mission is to foster expertise in the development and production of recombinant human laminins (key proteins enabling researchers and biopharma to grow, manipulate, and engineer both stem cells and certain primary cells). A feat that has previously been a struggle for scientists.
The company has created a product collection of cell culture matrices that can be used for culture applications and research, these products are now being sold to academic and industrial scientists globally. A turning point in early 2023 was the opening of a new premises scaling BioLamina’s product production and responding to growing demand.
Recent movement within the leadership team brought on new CCO Dr. Mattias Gäreskog with a wealth of knowledge in the commercial fields. Alongside this development the company has received funding to proceed expanding operations and its R&D sector to continue to help enable scientific progress in the space.
Steph
Company Specialist at Welcome to the Jungle
Sep 2023
$17.9m
EARLY VC
Oct 2021
$3.7m
EARLY VC
Kristian Tryggvason
(Board Member)Founder and current CEO of Alder Therapeutics and a Senior Advisor for NorthX Biologics. Prior to BioLamina worked as a Commercial Manager at Orexo AB.